PureTech Share News (PRTC)

TRADING UPDATES: Eagle Eye signs new John Lewis deal, Neometals update

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on xxxday and not separately reported by Alliance News:

UK earnings, trading statements calendar - next 7 days

PureTech Health's Vedanta Biosciences boasts "promising" results

(Alliance News) - PureTech Health PLC on Monday said that its founded entity, Vedanta Biosciences, has seen positive results for its lead programme, VE303.

LONDON MARKET MIDDAY: Bank of England lifts rates by 25 basis points

(Alliance News) - Stock prices in London were largely lower at midday on Thursday, raised UK interest rates by 25 basis points on Thursday, as widely expected, and indicated that further tightening in monetary policy may be required.

PureTech Health says Royalty Pharma acquires Karuna Royalties

(Alliance News) - PureTech Health PLC on Thursday said Royalty Pharma PLC has acquired an interest in PureTech's royalty in Karuna Therapeutics Inc's KarXT schizophrenia treatment.

US Royalty Pharma strikes deal with PureTech Health on KarXT royalties

(Sharecast News) - US-listed Royalty Pharma has acquired an interest in PureTech Health's royalty in Karuna Therapeutics' KarXT drug for up to $500m, with $100m in cash up front and up to $400m in additional payments contingent on the achievement of certain regulatory and commercial milestones.

PureTech Health says Karuna KArXT trial receives positive results

(Alliance News) - PureTech Health PLC on Monday said its founded entity, Karuna Therapeutics Inc announced its phase 3 EMERGENT-3 trial of KarXT in Schizophrenia has met its primary endpoint.

TRADING UPDATES: Eco Atlantic swings to loss; Curtis approves takeover

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Monday and not separately reported by Alliance News:

IN BRIEF: PureTech Health to start trials for anxiety, depression drug

PureTech Health PLC - clinical-stage biotherapeutics company - Says it will advance LYT-300 for the potential treatment of anxiety disorders and post-partum depression. A placebo-controlled, phase 2a, proof-of-concept, social anxiety clinical trial is expected to begin in the first half of 2023. Results are expected by the end of the year. An open-label, phase 2a, proof-of-concept clinical trial in women with post-partum depression is expected to begin in the second half of 2023.

PureTech's Alkili reports success in adolescent ADHD study

(Sharecast News) - Clinical-stage biotherapeutics investor PureTech Health announced on Friday today that its digital medicine company Akili, which it founded, announced topline results of the 'STARS-ADHD-Adolescents' label expansion study evaluating the efficacy and safety of 'EndeavorRx', or 'AKL-T01' in adolescents aged 13 to 17 with attention-deficit hyperactivity disorder (ADHD).

PureTech says ADHD treatment shows improved attentional functioning

(Alliance News) - PureTech Health PLC on Friday said the topline results for the pivotal trial of its EndeavorRx treatment showed "robust improvements in attention and broader clinical outcomes".

TRADING UPDATES: Fiinu teams with TransUnion; GRC wins pact

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Monday and not separately reported by Alliance News:

PureTech entity Sonde raises USD19.3 million in investment round

(Alliance News) - PureTech Health PLC on Friday said that its founded entity, Sonde Health Inc, has completed a Series B investment round for the development of its voice-based health monitoring technology.

PureTech founded entity Vor Bio first AML patient gets transplant

(Alliance News) - PureTech Health PLC on Thursday announced that its founded entity Vor Biopharma Inc has successfully transplanted its investigational trem-Cel into a patient with acute myeloid leukemia.

PureTech Health advances new therapeutic candidate to clinical studies

(Alliance News) - PureTech Health PLC on Wednesday said that it had advanced LYT-310, an oral form of cannabidiol (CBD) prodrug toward clinical studies.